E*TRADE View E*TRADE Products & Accounts Help

*
Accounts
*
Investing
*
Tools &
Research

Quote:
Logoff

*
Markets
* |
*
News
*
Company Profile
*
Charts
* |
*
Stock Screener
* |
*
Heat Maps
* |
*
Performance Tables
* |
*
Technical Analysis


14 Dec, 2009 15:41 UK
Symbol Lookup
FTSE 1005,309.2847.71
Close

* Snapshot
* Charts
* Prices
* Trades
* News
* Broker Views
* Director Dealings
* Star Ratings
* Fundamentals
* Profile

XCounter AB (XCT) Buy Now Sell Now
Annual Report

Sector:
Health Care Equipment & Services

Share Price
5.50p

Change Today
0.000p

Market Cap
2.40m

* Overview
* Regulatory News
* ShareCast

Subsidiary signs major development agreement

RNS Number : 0851E
XCounter AB
14 December 2009




PRESS RELEASE




XCounter's subsidiary signs major development agreement to supply innovative monitoring detectors to the energy industry


Stockholm, 14 December 2009: XCounter AB (AIM: XCT) ('XCounter' or 'the Company'), a leader in the development of photon counting detector and tomosynthesis-based 3D imaging technology, today announces that its subsidiary, Oy AJAT Ltd ("AJAT"), has signed a seven year exclusive agreement to supply its X-ray detector technology to a Norwegian company specializing in industrial technology development within the energy industry (the "Commercial Partner").

Pursuant to the agreement, AJAT will receive orders with minimum purchase values increasing each year up to and including 2015 and worth in aggregate 8.2m. The Commercial Partner has the option to extend the contract by two years on three occasions up to a total of six years.


AJAT and the Commercial Partner will work together on the development of these new detector products and other related technologies with broader applications to the energy industry.


AJAT and the Commercial Partner have been working together and have already completed the first stage of the customized technology for detection devices.


This agreement is a major step in XCounter's strategy to focus on specialty digital detector technologies for medical, dental and industrial applications.


XCounter owns 49.8% of AJAT and has a call option for the remaining 50.2%.

Mikael Strindlund, CEO of XCounter commented:


"Today's announcement is a further validation of our focus on developing and marketing specialty X-ray detector technologies for different application fields. We are delighted to have entered into this long term agreement and are looking forward to further developing our relationship with this key customer.

current mkt cap does not even cover cash.220p highs and contracts now coming from offshore oil techno companies.

Oy Ajat Ltd, Developer of Digital Radiation Cameras, Acquired by Swedish Company

Swedish company XCounter AB, which is listed on the AIM stock exchange, has acquired almost one-half of the Finnish technology company Oy Ajat Ltd. Vendors in this transaction, in addition to Ajats executive management, are Finnish Industry Investment Ltd, which divested all its holding in the company, and also Thomcapital Oy.

Ajat develops and sells digital radiation imaging cameras for dentistry, medical applications and industrial use. Most notably, Ajats technology has been highly successful in dental X-ray applications. The companys cameras are far more precise and faster than their market contenders and can, for example, inspect in real-time products moving on a conveyor belt.

"With customers in Europe, Asia and the USA, Ajat is an excellent example of a growth company that has succeeded in globally commercialising Finnish-developed technology," says Finnish Industry Investment Ltds Investment Manager Heli Kukko.

Established in 2002, Ajat today employs 18 people. In 2008 the Espoo-based company generated net sales of over MEUR 3 and posted a profit.

For more information:

XCounter AB and Artemis Imaging GmbH to develop breast CT scanner
PostDateIconWednesday, 08 July 2009 09:35 | PDF Print E-mail
Company News - XCounter AB

XCounter AB to join Artemis Imaging GmbH on the development of an innovative 3D Breast CT system

XCounter AB (publ) (AIM: XCT), a technology leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging, announced it is working with Artemis Imaging GmbH, a spinoff of the University of Erlangen's Institute of Medical Physics, on the development of an innovative 3D Breast CT system. The new device may have the potential to offer more comprehensive and higher quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found in women.

Artemis Imaging GmbH, under the leadership of Prof. Willi Kalender, has substantial expertise and a proven track record in CT physics, system and applications development. It intends to develop, validate, clinically test and commercialize a low-dose, high-resolution breast CT scanner using the XCounter digital direct conversion solid state detector technology.

The new device will offer multiple views of the breast, while XCounter's photon counting technology will increase the overall quality of imaging.

Prof. Willi Kalender, CEO of Artemis Imaging GmbH stated: "We selected the XCounter photon counting technology because we believe it meets the requirements for a revolutionary new dedicated breast CT system which combines the highest image quality with the lowest
radiation dose to the patient."

Mikael Strindlund, CEO of XCounter commented:

"Today's announcement is further validation, by world-renown experts, of our leading photon counting solid state detectors and its potential to assist in the earlier identification of one of the most common forms of cancer."

XCounter's technology includes recently acquired AJAT technologies and XCounter's photon
counting technology. Artemis Imaging GmbH aims to qualify the technology as soon as it becomes available; a first detector has already been ordered for evaluation.

Background


XCounter is a technology leader in the development of photon counting X-ray detectors and tomosynthesis based 3D medical imaging based on its proprietary X-ray technologies.


In May 2009, XCounter acquired 49.8% of the issued shares of AJAT, a revenue generating company based in Finland with a detection technology that complements XCounter's existing photon counting technology. Under the terms of the acquisition, XCounter obtained board control of AJAT and, in July 2009, completed the acquisition of a call option to acquire all remaining and outstanding shares in AJAT. It is the Board's current intention to exercise the call option subject to Shareholder approval which will be sought at the Company's Annual General Meeting in April or May 2010.


AJAT develops and commercialises in-house, cutting-edge digital X-ray imaging detectors for dental and industrial applications using a unique technological approach to digital X-ray imaging based on Cadmium Telluride (CdTe) and Cadmium Zinc Telluride (CdZnTe) Complementary Metal Oxide Semiconductor technologies. AJAT acts as a supplier of digital X-ray detectors to OEMs providing its detectors and software technologies to OEM partners to integrate them into end-user imaging systems and as a dental extra-oral imaging system provider using manufacturing partners to integrate the AJAT detectors into complete systems which are then sold under the AJAT brand and model name ("ART Plus").


The Directors believe that XCounter and AJAT's technologies are well positioned to address the growing interest in the reduction of radiation dose for medical imaging and increase in quality of images for medical diagnosis and imaging support, dental as well as increasing use of X-ray technology in industrial applications.Artemis has applied for a 2.8m grant from the German government (Bundesministerium f Bildung und Forschung) to fund half of the project. It is currently anticipated that the German government will announce the results of the grant application on or around 26 January 2010.


If Artemis' application for the grant is successful, the Company anticipates negotiating and signing a co-development agreement with Artemis in the first quarter of 2010 which will include provisions granting Artemis exclusivity for the PCT technology for the Mammo CT application. Following the developmental phase, Artemis proposes to licence the product to a major OEM and it is XCounter's current intention at that time to enter into a supply agreement with Artemis, so as to exclusively manufacture and supply the detector components to be integrated into the completed Mammo CT deviceIndustrial applications


AJAT has confirmed several new orders with industrial applications including small animal CT scanning, inspection systems for food and oil pipe welds. The Directors believe that AJAT will continue to grow its orders in this segment.


In particular, the Company announced earlier today that AJAT has signed a seven year exclusive agreement to supply its X-ray detector technology to a Norwegian company specializing in industrial technology development within the energy industry (the "Ajat Commercial Partner").


A member of the group of the AJAT Commercial Partner has agreed to subscribe for 11,818,181 Placing shares at the Placing Price.The AJAT acquisition has exceeded the Board's expectations regarding profit and is in line with expectations for revenues in the first six months since completion. Exciting new orders, especially within industrial applications, strengthens the Group's business pipeline in both the short and medium term.


In the 12 months ended 31 August 2009, AJAT reported operating profit of 414,000 (unaudited) and total revenues of approximately 3.5m (unaudited). These revenues came largely from dental and industrial applications. AJAT's detectors are integrated by OEMs in different system applications, spanning from dental panoramic cephalometry, and 2D and future 3D medical imaging. In addition, since its launch in August 2008, AJAT's dental 2D end-user system "Art Plus" has sold 86 units.


AJAT is a profitable business with high growth opportunities within its core dental applications but also within the field of industrial applications such as inspection systems for food production, inspections of welds for the oil and gas piping industry and small animal imaging for the pharmaceutical industry. The Directors believe that AJAT will generate revenues of 4 million and EBITDA of approximately 550,000 (14 per cent. of sales) during the 12 months ending 31 December 2009, a 13 per cent. increase on revenues for the 12 months ended 31 December 2008

Site Search
Register Community Message Board Buy Books Rumour Mill Stock Quotes Stockwatch Subscriptions SuperMarket Level
Welcome oilbrat. Free Board Crazy Board My Home
Warning Statement FAQ Calendar

Preview Post
The following is a preview of your post. If everything looks ok then you can click 'Ok, submit' and your post will be entered. If not then use the bottom form below to edit some more.


* Re: XCOUNTER AB/XCT ABSOLUTELY INCREDIBLE NEWS


http://saferay.co.uk/FirstWeb/public/consortium/AJAT.aspxAJAT - Finland

SMEP profile: AJAT is a specialised NDT engineering company with 12 full-time employees that designs, develops and manufactures in house, X-ray digital imaging cameras. AJATs technology is cutting edge and is based on CdTe or CdZnTe bump-bonded to an ASIC. AJAT founded on 2001, this young company already has strong national and international connections and is located at Espoo, Finland. In Fiscal 2003 ending 8-2003 AJAT had revenues of approx. 400kEuro selling its innovative cameras. The company has invested over 2million Euros over the past two years in ramping development and production facilities and developing its products. It appears that AJAT is today in a unique position world-wide to provide direct conversion X-ray cameras based on CdTe-CMOS technology. The revenues for Fiscal 2004 are expected to be in excess of 800k Euros.

The research at AJAT is mainly centred on quality control and monitoring often for bespoke applications. NDT is performed primarily by use of X-ray imaging and X-ray energy dispersive measurements. Service inspection is performed, based on samples submitted for structural integrity assessment according to the customers specific demands. These services are directed towards NDT quality control checks, spot tests for structural integrity / quality assessment, evaluation of internal geometry and for selection of samples and sample volumes for destructive (e.g. mechanical) tests.

Role in project and reason for participation: WP-B Manager: (PSC): Dr. Konstantinos Spartiotis, who holds a PhD in Physics, is the CEO and chairman of the company and will be a key member of the PSC. AJAT will develop and implement the next generation of direct conversion Dynamic Imaging X-ray camera, including a scanning solution. AJAT are in a unique position to achieve this by virtue of their experience and expertise in this field. The reason for participation is that AJAT wish to maintain the lead position they have built for themselves at a cost level they cannot maintain internally. The dissemination of their technology, particularly in such a large industrial sector is seen as a huge opportunity. The primary commercial interest lies in the market opportunities for fast highly accurate digital inspection technology. The current situation is that systems have to be demonstrated before they are adopted, and R&D efforts and hence costs are too high to enable SMEs to take a role in this regard. Detector technology developed to this level will result in significant international sales

ART plus the world's best digital panoramic X-ray device, image quality is the x-ray machine. Bunun sebebi, t dyada kullanılan CCD teknolojisinin yerine AJAT tarafından geliştirilen ve k daha iyi gtalabilen CdTe (Cadmium Telluride) sens kullanmasıdır. The reason for this, instead of CCD technology is used all over the world developed by AJAT much better image that can receive and CdTe (Cadmium Telluride) sensor is used. Dyada bu ileri teknoloji senskullanan tek cihazdır ve gter bariz bir şekilde daha nettir. This is the only device that uses advanced sensor technology in the world and images are clearly sharper. CdTe (Cadmium Telluride) diğer CCD sensler gibi okside olmaz, yani 1 inci g ile 10 yıl sonra alacağınız gtaynıdır. CdTe (Cadmium Telluride) is not oxidized like other CCD sensors, ie 10 years after the 1st day you receive the image is the same. ART plus kontrol panelinde kV ve mA ayarlamalarının yapılabildiği gibi zaman ayarı da yapılabilir. ART plus control panel, such as kV and mA when setting adjustments can be made as well. Senekler k fazla geniştir ve kullanıcıya kaliteli gtalınabilmesi in t imkanları sunar. Options too wide and can be user-quality images for all possible rates. Gtkalitesi HD (High Definition) olarak tarif edilebilir. Image quality HD (High Definition) can be described as. Yetişkin ve cuk panoramiğinin yanı sıra sağ, sol ve orta kesit yada bunlardan herhangi ikisinin kimlerini yapabilir. Adults and children, as well as panoramic right, left and middle sections, or any two of them can make shots. Ak ağız ve kapalı ağız TMJ kimi ve maxiller sin kimi yapabilir. Open mouth, closed mouth, and TMJ can capture and capture maxiller sinus.

ART plus ileri teknolojinin ve gdeki hiir cihaz ile mukayese edilemez. ART is the product of advanced technology and present plus any device and can not be compared.

Biz bu teknolojiye Volumetrik Panaromik diyoruz. We call this technology Volumetric Panoramic.

CdTe teknolojisi ile beraber gelen glyazılım panaromik makine sanayine basamak atlattı. Powerful software that comes with a panoramic camera CdTe technology industry digits survived.

4 cm kalınlığında alınan veri erinden yaratılan kusursuz panaromik gter CdTe sens gden kaynaklanmaktadır. 4 cm thick, the received data generated through the sensor's power stems from CdTe perfect panoramic view.

Buge kadar kullanılan sensler ile ancak belirli dlem erinde gtalınabilirken, ART Plus geniş bir hacim sunmakta. Until now the sensors used on the plane with a certain image and can be taken, ART Plus offers a wide volume. Kıyaslamak istersek volumetrik gteme teknoloji diyebiliriz. Volumetric imaging technologies can say we want to compare.

Teknik ellikler; Specifications;
*CdTE sens (CdTe (Cadmium Telluride sens ) * CdTE sensor (CdTe (Cadmium Telluride sensor)
*Piksel boyutu:100 um x 100 um * Pixel size: 100 um x 100 um
*Gri Tonlama: 16 bit * Grayscale: 16 bit
*lışma Sistemi: Windows XP professional ,Vista ( Gri tonlama 32bit) * Operating System: Windows XP professional, Vista (32bit gray scale)

Implant Planlama Yazılımı dahildir. Implant Planning Software is included.
DICOM uyumlu DICOM compatible
TWAIN uyumlu TWAIN compliant
Ağırlık: 200kg Weight: 200kg
Garanti Sesi : 2 yıl Warranty Period: 2 years
etim Yeri: Finlandiya Production Location: Finland


CdTe Sens diğerlerinden Farkı ? CdTe sensor differ from others?

NEDEN CdTe SENS ? WHY CdTe SENSOR?

CdTe-Sens Teknolojisi CdTe-Sensor Technology

ART Plus teknolojinin son olan ekstra ağız i dijital gteme sistemini tanıtmakla gurur duymaktadır.En yeni CdTe (Cadmium Telluride) sens teknolojisi tek bir panaromik kesit alınırken saniyede 300 tane farklı alardan gtsağlamaktadır.Bu gter paralel olmayan,net ve farklı panaromik gterini oluşturması in kombine edilmiştir. ART Plus technology, the end product of the extra oral digital imaging system duymaktadır.En proud to introduce the new CdTe (Cadmium Telluride) sensor technology, a single panoramic cross-section while the second received 300 grains from different angles to view the image sağlamaktadır.Bu unparalleled, clear and different panoramic images to form were combined.

CdTe-sens teknolojisi eşsizdir ve diğer radyoloji dental sensleri gibi değildir.Bunun sebebi ise CdTe sens X-ışınlarını ışığa virmez.Direk olarak elektronik sinyallere virir,dolayısıyla gter bulanık değildir ve gtnetliği ve kontrastı %300'e kadar artmaktadır. CdTe-sensor technology is unique dental radiology sensors and other reasons, such as değildir.Bunun the CdTe sensor X-rays to light as virmez.Direk translates into electronic signals, so the images are blurred and the image sharpness and contrast up to 300% increase.
Yanlış pozisyonlama nedeni ile bulanık olan gter yada anatomikal ellikleri yetersiz olan cihazları kullanarak kilmiş gteri teşhis etmek gerkten zordur.Teknolojinin son olan Art Plus panaromik cihazının otomatik ve manuel yakınlaştırma elliğini kullanarak bu tarz gteri tekrar kesit almaya gerek kalmadan kolayca teşhis etmesini sağlamaktadır Cause incorrect positioning of the blurry images or poor anatomikal features of the device by using the drawn images to diagnose zordur.Teknolojinin really the end product of the Art Plus panoramic device with automatic and manual zoom feature using this kind of cross-sectional images to take back without the need to easily diagnose provides

* Systems
* Sensors (OEM)
* Retrofit Sensors

ART Plus Panoramic Imaging System



Technology

ART Plus is a Panoramic Dental Imaging system incorporating AJATs unique CdTe-CMOS sensor technology and software. ART Plus delivers outstanding image quality, sharpness and contrast resolution combined with advanced functionality and diagnostic tools. The ART Plus dental systems truly address the market need for high quality at affordable cost. The complete product brochure can be downloaded from here.

ART Plus represents a new generation of extra-oral dental X-ray imaging systems. The new CdTe (Cadmium Telluride) sensor technology provides up to 300 individual images per second during a single panoramic exposure. These images are combined to produce multiple panoramic layers of unparalleled quality and clarity.

CdTe-sensor is a unique technology that, unlike any other dental radiology sensor, directly converts X-rays to electronic signals. X-rays are not converted to light, therefore no blurring occurs and image clarity and contrast are increased up to 300 %.

Blurred images with mispositioned patients or unclear images with specific anatomical features that were difficult to diagnose using conventional panoramic systems, can now be easily resolved without additional exposures, using ART Plus autofocus or manual focus features.

Benefits

Up to 300 % Better Image Quality
Up to 3 times less radiation
Auto & Manual Focus
2D Rotation
Multi Focal Layer Imaging
TWAIN & DICOM Compliant
Spine Compensation
Quick Real Time Imaging

XCounter AB (publ) (AIM:XCT), a technology leader in the development of tomosynthesis-based 3D medical imaging, announced positive initial results from the first clinical evaluation of its innovative breast screening device XC Mammo - 3T. The device is the world's first dedicated 3D digital mammography system for the detection of breast cancer, the most common form of cancer found in women.

Conducted in April 2009, the independent study by the mammography departments of Danderyd University Hospital and the Karolinska University Hospital evaluated the clinical benefits of using the new tomosynthesis-based 3D imaging compared with traditional 2D digital mammography. The study was based on 150 patients, each selected on the basis they required additional scanning due to suspicious lesions found during initial scans.

The results indicate that the XC Mammo - 3T, offers the same sensitivity from one tomosynthesis image compared to two images from 2D digital mammography, despite the fact that the patient selection was based on the 2D images by expert radiologists that currently have limited training in reading tomosynthesis images.

Dr. Gunilla Svane, associate professor of radiology at Karolinska University Hospital highlighted the XC Mammo - 3T prototype demonstrated a number of benefits over traditional 2D imaging: "One of the major limitations of 2D images is that it is difficult to discern individual features in dense breasts which mean that we may get false negative findings. The tomosynthesis technique makes each structure stand out in a way which makes it easier to detect tumours. In the 3D images the extent of the feature is also more obvious, particularly for spiculated masses. Micro-calcifications are as clearly visible in the XC Mammo -3T images as they are in 2D. In addition, it is easier to see the extension and the growth pattern of the calcifications in the three dimensional representation than in the 2D images where one is limited to two views."

Dr. Edward Azavedo, associate professor of radiology at Karolinska University Hospital continued: "The ability of the XC Mammo -3T images to detect malignancy is just as high as the 2D images. However, the possibility to single out masked lesions in dense breasts also means that we will probably be able to detect more abnormalities and cancers in this category without additional examinations, such as ultrasound. The patient response has been very positive and the patients have stated that the 3D examination was much more comfortable than the regular 2D exam where amongst other things the compression force on the breast in general is higher".

Mikael Strindlund, CEO of XCounter said:
"The positive results of our first prototype installation in a clinical environment is a major achievement for XCounter. I am particularly encouraged to hear that, unlike other imaging systems, XC Mammo - 3T can confidently detect micro-calcifications, helping to identify abnormalities earlier in their development."

The findings from the independent clinical evaluation will be developed into a comprehensive clinical report during 2009.

XCounter AB (publ) (AIM: XCT), a technology leader in the development and
commercialisation of 3D medical imaging, has announced a commercial partnership
with the global leader in brachytherapy, Nucletron B.V.


In this first step of the cooperation between Nucletron and XCounter, the latter will evaluate
the properties of a novel imaging system for brachytherapy treatments. This evaluation is a
pre-study prior to moving to a full agreement on the development of a dedicated imaging
system for brachytherapy, especially designed for Nucletron.


The incidence of most cancer types is growing. Approximately 50% of all men and 30% of
all women in the USA will develop some kind of cancer at some point in their lives (NIH,
2002). This means that the need for effective methods for cancer treatment, such as
brachytherapy, is growing rapidly.


High image quality and low dose imaging are vital components in precision cancer
treatment. We find XCounters imaging principles very attractive and are looking forward to
the results of this pre-study, says Dick van Waes, Business Director Brachytherapy and
Imaging of Nucletron.


It is with great pleasure that we can announce XCounters commercial partnership with
Nucletron. Nucletron has chosen to cooperate with XCounter as a result of our unique
imaging concepts, as well as our ability to handle development on behalf our customers. In
line with our business concept, which is to invent and develop innovative patient and disease
specific imaging systems and concepts for leading medical companies, the agreement is a
further recognition of the capabilities of our company as we continue partnering discussions
for the XC Mammo -3T, says Tom Francke, CEO at XCounter. We are looking forward to a
fruitful cooperation with Nucletron.


Brachytherapy is a high precision, minimally invasive radiation therapy, favourably used for
cancer treatment in parts of the body which have sensitive adjacent organs. Examples of such
treatment areas are gynaecological body sites, breast, bladder, brain, head and neck, lung,
esophagus and prostate

XCounter's subsidiary signs major development agreement to supply innovative monitoring detectors to the energy industry


Stockholm, 14 December 2009: XCounter AB (AIM: XCT) ('XCounter' or 'the Company'), a leader in the development of photon counting detector and tomosynthesis-based 3D imaging technology, today announces that its subsidiary, Oy AJAT Ltd ("AJAT"), has signed a seven year exclusive agreement to supply its X-ray detector technology to a Norwegian company specializing in industrial technology development within the energy industry (the "Commercial Partner").

Pursuant to the agreement, AJAT will receive orders with minimum purchase values increasing each year up to and including 2015 and worth in aggregate 8.2m. The Commercial Partner has the option to extend the contract by two years on three occasions up to a total of six years.


AJAT and the Commercial Partner will work together on the development of these new detector products and other related technologies with broader applications to the energy industry.


AJAT and the Commercial Partner have been working together and have already completed the first stage of the customized technology for detection devices.


This agreement is a major step in XCounter's strategy to focus on specialty digital detector technologies for medical, dental and industrial applications.


XCounter owns 49.8% of AJAT and has a call option for the remaining 50.2%.

Mikael Strindlund, CEO of XCounter commented:


"Today's announcement is a further validation of our focus on developing and marketing specialty X-ray detector technologies for different application fields. We are delighted to have entered into this long term agreement and are looking forward to further developing our relationship with this key customer."

Picturing Change
As imaging technology advances, the ways in which healthcare professionals do their job also changes. But what are the next big developments to come out of R&D and how will they impact on the role of the radiologist? GlobalData looks at the work being undertaken by manufacturers and academia and how it is changing the face of diagnostic imaging the world over.

Date: 08 Oct 2009
Email Article

Print

Link to us
Link To Us

Precision and diagnostic accuracy will be the key factors deciding acceptance and market penetration of about 176 diagnostic imaging devices currently at various stages of development. This article uses the Medical eTrack Products Pipeline Database to identify those products and technologies that are expected to revolutionalise the way healthcare professionals diagnose and treat life-threatening conditions.

Mammography
There are about 24 mammography products under different stages of clinical investigations, but the following devices, when launched, are the ones expected to make diagnosis of breast cancer more accurate with minimum instances of false positives and false negatives.

Digital breast tomosynthesis (DBT)
Being developed independently by GE Healthcare, Siemens Healthcare, the US-based Hologic and the UK-based Dexela Limited, the DBT-based mammography system acquires, processes and visualises data from 3D X-ray images making it easier than ever before to detect tumors even in dense breast tissues. DBT reconstructs a 3D composite image from a series of 11, low-dose 2D images, enabling physicians to view the interior of the breast without hindrance from surrounding superimposed breast tissues.

This results in identification of tumors that are easy to miss with the conventional 2D approach. Currently under clinical investigations, the system, once approved, is expected to redefine the breast cancer diagnosis and treatment landscape.

Computed tomography laser mammography (CTLM) system
Currently under development, the CTLM system from Imaging Diagnostic Systems Inc. is a non-invasive device that uses lasers to image the breast. Unlike an X-ray mammography system, CTLM images blood haemoglobin and the process of new vessel formation, a physiological development often associated with breast cancer.
"The CTLM system is a non-invasive device that uses lasers to image the breast."

The system images through breast implants and dense breast tissue easily, which traditional mammography finds difficult to penetrate. With its ability to visualise tumors in the evolving process, CTLM is expected to provide early diagnosis and hence early treatment, leading to breast-sparing surgery and less trauma to the patient.

Imaging Diagnostic Systems, Inc. is currently collecting data from clinical sites for the future filing of a US Food and Drug Administration (FDA) Premarket Approval (PMA) for its CTLM system.

Amulet full field digital mammography (FFDM) system
Fujifilm Corporations Amulet is the worlds first digital mammography system equipped with the direct conversion flat panel detector (FPD) technology. The system provides a small pixel size of 50m yet produces both high-resolution and low-noise images, making image quality its key feature.

The product is also said to offer the opportunity for reduced dose and enhanced workflow efficiency. Already launched in Japan, it is awaiting FDA approval nod for sale in the US, where it is expected to be marketed under the Aspire brand of breast imaging products.

The US launch of this system will make Fujifilm the first womens healthcare company offering both computed radiography (CR) and digital radiography (DR) FFDM solutions.

Computer tomography (CT)
Dominion Vi 3D medical imaging scanner
The Dominion Vi 3D medical imaging scanner being developed by the Californian-based Imaging3 Inc. employs high-resolution photo-fluoroscopy to produce 3D diagnostic images on a real-time basis. Since these images are produced real time, they have the potential to be used for any current or new medical procedure that requires multiple frames of reference to perform the procedure in the human body.

In April 2008 Imaging3 received the US FDA approval to begin distributing the product for evaluating its effectiveness in the clinical setting. Touted by the company as a safer and cost-effective alternative to CT scanning, the device stands to benefit many medical specialities, including trauma, cardiology, pain management, paediatrics, orthopaedics, sports medicine, vascular, and neuro-vascular.

Magnetic resonance imaging (MRI)
There are about 20 MRI systems at various stages of development that will transform the MRI technology landscape. Several, however, are expected to revolutionise MRI-based diagnosis.

11.7T MRI system
Being developed by the French Atomic Energy Commission (CEA) in collaboration with Siemens Healthcare and Alstom Magnets and Superconductors, within the framework of the French-German consortium Iseult/INUMAC (Imaging of Neuro disease Using high field MAgnetic resonance and Contrastophores), the 11.7T MRI system is expected to address clinical applications of ultra high-field (UHF) MRI.

7T MRI system
The 7T MRI system, while offering the potential for microscopic spatial resolution, also enables the observation and analysis of tissue metabolism and function.

A Siemens Healthcare development, 7T MRI systems are investigational devices and are not available for clinical use. Currently, they are being used only for clinical research and not for clinical diagnosis.

It is expected that the 7T MRI system will make it possible to study neuronal function at the sub-millimeter scale. Potential clinical applications include neurodegenerative diseases like Alzheimers.

Renaissance system 1000
The product of a partnership between US-based ViewRay, Inc. and Siemens Healthcare, the Renaissance System 1000 combines MRI and gamma ray radiotherapy technologies to provide real-time beam-on imaging and targeting of the tumor.

MRI coil devices
Being developed by the US-based Tursiop Technologies LLC, the nanomaterial-based MRI coil devices are expected to produce better image quality and faster scan times, thus boosting the functional capabilities of any installed MRI system.

X-ray
XCT -3T
XCounter AB from Sweden is behind the XCT -3T, a 3D digital tomosynthesis technology that captures 3D digital X-ray images, resulting in high-resolution imaging at low levels of radiation. The Swedish company is pursuing the development of four systems.

They are the XC Mammo -3T, a prototype system for 3D digital breast tomosynthesis screening; the XC MP-3T, a 3D general-body imaging system; XC Cardio -3T, a cardiac-imaging system designed for 3D functional imaging of the heart; the Cardio -4T, a cardiac-imaging system designed for repetitive 3D imaging of the heart.

Magnetic particle imaging (MPI)
Magnetic particle imaging (MPI) technology uses magnetic properties of iron-oxide nanoparticles injected into the bloodstream to generate real-time images of arterial blood flow and volumetric heart motion. Because the human body doesnt naturally contain nanoparticles, the MPI technology, by combining high spatial resolution with short image acquisition times, captures dynamic concentration changes as the nanoparticles flow along with the bloodstream.

Currently in pre-clinical stages, the first 3D imaging results with this system were announced by Philips Healthcare, the company developing the technology, in March 2009. The company was the first in the world to demonstrate the use of MPI in producing real-time in-vivo images, which capture cardiovascular activities, accurately and in real-time.

It noted that by augmenting important functional details to the anatomical data obtained from conventional modalities such as CT and MR, the MPI technology has the potential to help in the diagnosis and treatment planning of major cardiovascular diseases such as atherosclerosis and congenital heart defects.
"Scientists have invented a magnetic molecule, Fe8, that is a highly effective contrast solution with potential to be used in medical imaging."

Academia in action
MRI/PET scanner
Researchers at the University of California, Davis Campus in the US have successfully combined the technological capabilities of positron emission tomography (PET) and magnetic resonance imaging (MRI) to build a single scanner the MRI/PET scanner. While combination scanners that combine computer-assisted tomography (CAT) and PET scans are already available in the market, the fact that CAT scans provide less structural details (especially of soft tissues) than MRI scans, makes the MRI/PET scanner a breakthrough technology, which is under development. As standalone units, MRI scans provide high-quality structural images but hardly any functional detail; whereas PET scans show body processes but no structural detail.

Fe8 Scientists at the National Institute of Standards and Technology in collaboration with researchers at the Florida State University and the University of Colorado at Boulder in the US have invented a magnetic molecule, named Fe8, that is harmless, predictable and thus a highly effective contrast solution with potential to be used in medical imaging.

As should be clear from our product and technology profiles, precision and diagnostic accuracy remain the key innovation areas of interest, and its not just the imaging giants but also the small and medium manufacturers that are expected to bring dynamism to the diagnostic imaging technology landscape.

imaging on the way

There are 176 diagnostic imaging devices currently at various stages of development.

About 24 mammography products are under different stages of clinical investigations at present.

It is estimated that some 20 MRI systems are at various stages of development.

In 2008 the global diagnostic imaging market was worth $16bn.

State of the global diagnostic imaging market

In 2008 GE Healthcare, Philips Healthcare and Siemens Healthcare together accounted for more than 70% of the global diagnostic imaging market, which was valued at $16 billion. With a combined pipeline portfolio of about 20 products at different stages of clinical investigations, GE, Philips and Siemens are well positioned to further penetrate a market that is forecast to grow at 6% annually for the next seven years to reach $24.2 billion by 2015.

Source: Medical eTrac

http://docs.google.com/viewer?a=v&q=cache:TARtNRQtTtUJ:www.xcounter.se/uploads/xcounter/pdf/090325XCT%2520Acquisition%2520of%2520AJAT%2520-%2520FINALCLEAN%2520_2_%2520homepage.pdf+XCOUNTER+AB/admission+document&hl=en&gl=uk&pid=bl&srcid=ADGEESjjBLF3xPb3SoNGQzOWPtUKjytW9cruPShm7xOuyT8MK9kHfUV5nGKMNtQM7DgpvLt6a2yOHVvM3Fw2KIS-jhPvQnKrF867E8fKQ1vFaTWebi5vtWxMJJq-pZZw7SwFqMzQetvc&sig=AHIEtbSjl8K67nU1Z4CrYj0gWUDjKz_1KQ

http://www.mandadeals.co.uk/m-and-a-deals/international/1044157/xcounters-xray-vision.thtml
XCounters X-ray vision
By Patrizia Rossi on May 08 2009

XCounter AB, an AIM-traded Swedish developer of low-radiation 3D digital X-ray imaging technology, has acquired a 49.8 per cent stake in Oy AJAT, a Finnish manufacturer of digital solid-state X-ray detectors, for 3.4 million (3 million). XCounter is set to pay a further 1.05 million if certain performance targets are met.

The Swedish company has entered into option agreements with the company, which will give it the right to up its stake by 19 per cent in 12 to 18 months in exchange for 13 million shares in XCounter, representing some 30 per cent of the companys current issued share capital. The companys intention is to acquire 100 per cent of AJAT. However, details of how and when this will happen have not been released.

The acquisition brings AJATs solid-state detector technologies for the medical and industrial markets to XCounters product portfolio and propels the Swedish corporate into new markets, the company said.

Mikael Strindlund, CEO of XCounter, said: This is a very exciting acquisition, that creates the opportunity to build a world-class, sustainable X-ray detection business based on a leadership position in photon-counting technologies. The combination of XCounters and AJATs technologies will enable XCounter to open up new and exciting markets and allow the company to achieve its primary objective of creating value for shareholders.

3D medical x-ray company Xcounter arrives on AIM
by William Foss

Xcounter AB (XCT) hit the ground running on announcing it?s admission to AIM today.

The company raised 16 million before expenses at an IPO price of 155p/share, and on listing this morning the shares started trading at a 25% premium at 197p.

Xcounter has developed a new technology for capturing 3D X-ray images which create a considerably higher quality image combined with a lower radiation dose than tradition X-ray machines. The company intends to use the funds raised to complete the development and build the first units with the intention of targeting the mammography and general body imaging sectors of the health-care industry.

"Senses Working Overtime"

1st detector orderedXCounter AB



XCounter AB and Artemis Imaging GmbH to develop breast CT scanner



2 July 2009: XCounter AB (publ) (AIM: XCT), a technology leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging, today announced it is working with Artemis Imaging GmbH, a spinoff of the University of Erlangen's Institute of Medical Physics, on the development of an innovative 3D Breast CT system. The new device may have the potential to offer more comprehensive and higher quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found in women.



Artemis Imaging GmbH, under the leadership of Prof. Willi Kalender, has substantial expertise and a proven track record in CT physics, system and applications development. It intends to develop, validate, clinically test and commercialize a low-dose, high-resolution breast CT scanner using the XCounter digital direct conversion solid state detector technology.



The new device will offer multiple views of the breast, while XCounter's photon counting technology will increase the overall quality of imaging.



Prof. Willi Kalender, CEO of Artemis Imaging GmbH stated:
"We selected the XCounter photon counting technology because we believe it meets the requirements for a revolutionary new dedicated breast CT system which combines the highest image quality with the lowest radiation dose to the patient."



Mikael Strindlund, CEO of XCounter commented:

"Today's announcement is further validation, by world-renown experts, of our leading photon counting solid state detectors and its potential to assist in the earlier identification of one of the most common forms of cancer."


XCounter's technology includes recently acquired AJAT technologies and XCounter's photon counting technology. Artemis Imaging GmbH aims to qualify the technology as soon as it becomes available; a first detector has already been ordered for evaluation.

dtechinsight.com/ReportA409.html. It is a snapshot of the page as it appeared on 5 Dec 2009 22:09:03 GMT. The current page could have changed in the meantime. Learn more

Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer


Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009




Online Report Subscribers, Click Here

Pricing and Ordering Information

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles

According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.

The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.

As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.

This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.

Ordering Information

Title
Report# Publication
Date List Price

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies


A409


October 2009


$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.



TABLE OF CONTENTS



EXECUTIVE SUMMARY

i. Common Types of Breast Cancer

ii. Symptoms

iii. Risk Factors

iv. Early Detection

v. Treatment

vi. Risk Reduction

vii. Future Directions in Breast Cancer Detection

viii. Breast Cancer Detection and Diagnostic Technologies Market



Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit ES-6: Selected Limitations of Mammography

Exhibit ES-7: Selected Breast Cancer Imaging Technologies

Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013

Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier



1. CLINICAL overview

1.1 Common Types of Breast Cancer

1.2 Symptoms

1.3 Risk Factors

1.3.1 Benign Breast Conditions

1.3.2 Family/Personal History

1.3.3 Genetic Risks

1.4 Early Detection

1.5 Treatment

1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy

1.6 Risk Reduction

1.7 Future Trends in Breast Cancer Detection



Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit 1-6: Benign Breast Disease, by Category

Exhibit 1-7: Selected Benign Breast Diseases

Exhibit 1-8: Selected Limitations of Mammography

Exhibit 1-9: Selected Breast Cancer Imaging Technologies



2. MAMMOGRAPHY

2.1 Analog Mammography Systems

2.1.1 GE Healthcare/General Electric

2.1.2 Hologic

2.1.3 Planmed/Planmeca Group

2.1.4 Siemens Healthcare/Siemens

2.1.5 Others

2.2 Digital Mammography Systems

2.2.1 GE Healthcare/General Electric

2.2.2 Hologic

2.2.3 Siemens Healthcare/Siemens

2.2.4 Others

2.3 Computer-Aided Detection

2.3.1 Carestream Health/Onex

2.3.2 Hologic

2.3.3 iCAD

2.3.4 Scanis

2.4 Emerging Mammography Technology

2.4.1 BBN Technologies

2.4.2 Dexela

2.4.3 GE Healthcare/General Electric

2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings

2.4.5 Hologic

2.4.6 Imaging Diagnostic Systems

2.4.7 Philips Healthcare/Royal Philips Electronics

2.4.8 Sectra

2.4.9 Siemens Healthcare/Siemens

2.4.10 XCounter

2.4.11 Others

dtechinsight.com/ReportA409.html. It is a snapshot of the page as it appeared on 5 Dec 2009 22:09:03 GMT. The current page could have changed in the meantime. Learn more

Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer


Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009




Online Report Subscribers, Click Here

Pricing and Ordering Information

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles

According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.

The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.

As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.

This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.

Ordering Information

Title
Report# Publication
Date List Price

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies


A409


October 2009


$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.



TABLE OF CONTENTS



EXECUTIVE SUMMARY

i. Common Types of Breast Cancer

ii. Symptoms

iii. Risk Factors

iv. Early Detection

v. Treatment

vi. Risk Reduction

vii. Future Directions in Breast Cancer Detection

viii. Breast Cancer Detection and Diagnostic Technologies Market



Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit ES-6: Selected Limitations of Mammography

Exhibit ES-7: Selected Breast Cancer Imaging Technologies

Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013

Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier



1. CLINICAL overview

1.1 Common Types of Breast Cancer

1.2 Symptoms

1.3 Risk Factors

1.3.1 Benign Breast Conditions

1.3.2 Family/Personal History

1.3.3 Genetic Risks

1.4 Early Detection

1.5 Treatment

1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy

1.6 Risk Reduction

1.7 Future Trends in Breast Cancer Detection



Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit 1-6: Benign Breast Disease, by Category

Exhibit 1-7: Selected Benign Breast Diseases

Exhibit 1-8: Selected Limitations of Mammography

Exhibit 1-9: Selected Breast Cancer Imaging Technologies



2. MAMMOGRAPHY

2.1 Analog Mammography Systems

2.1.1 GE Healthcare/General Electric

2.1.2 Hologic

2.1.3 Planmed/Planmeca Group

2.1.4 Siemens Healthcare/Siemens

2.1.5 Others

2.2 Digital Mammography Systems

2.2.1 GE Healthcare/General Electric

2.2.2 Hologic

2.2.3 Siemens Healthcare/Siemens

2.2.4 Others

2.3 Computer-Aided Detection

2.3.1 Carestream Health/Onex

2.3.2 Hologic

2.3.3 iCAD

2.3.4 Scanis

2.4 Emerging Mammography Technology

2.4.1 BBN Technologies

2.4.2 Dexela

2.4.3 GE Healthcare/General Electric

2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings

2.4.5 Hologic

2.4.6 Imaging Diagnostic Systems

2.4.7 Philips Healthcare/Royal Philips Electronics

2.4.8 Sectra

2.4.9 Siemens Healthcare/Siemens

2.4.10 XCounter

2.4.11 Others